JP2023040241A5 - - Google Patents

Download PDF

Info

Publication number
JP2023040241A5
JP2023040241A5 JP2023003470A JP2023003470A JP2023040241A5 JP 2023040241 A5 JP2023040241 A5 JP 2023040241A5 JP 2023003470 A JP2023003470 A JP 2023003470A JP 2023003470 A JP2023003470 A JP 2023003470A JP 2023040241 A5 JP2023040241 A5 JP 2023040241A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023003470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023040241A (ja
Filing date
Publication date
Priority claimed from JP2019552040A external-priority patent/JP2020514386A/ja
Priority claimed from PCT/EP2018/057310 external-priority patent/WO2018172465A1/en
Application filed filed Critical
Publication of JP2023040241A publication Critical patent/JP2023040241A/ja
Publication of JP2023040241A5 publication Critical patent/JP2023040241A5/ja
Priority to JP2025031035A priority Critical patent/JP2025087764A/ja
Pending legal-status Critical Current

Links

JP2023003470A 2017-03-22 2023-01-13 ヒト化抗cxcr5抗体を使用するループスの処置 Pending JP2023040241A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025031035A JP2025087764A (ja) 2017-03-22 2025-02-28 ヒト化抗cxcr5抗体を使用するループスの処置

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762475173P 2017-03-22 2017-03-22
US62/475,173 2017-03-22
EP17306079 2017-08-18
EP17306079.9 2017-08-18
JP2019552040A JP2020514386A (ja) 2017-03-22 2018-03-22 ヒト化抗cxcr5抗体を使用するループスの処置
PCT/EP2018/057310 WO2018172465A1 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-cxcr5 antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019552040A Division JP2020514386A (ja) 2017-03-22 2018-03-22 ヒト化抗cxcr5抗体を使用するループスの処置

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025031035A Division JP2025087764A (ja) 2017-03-22 2025-02-28 ヒト化抗cxcr5抗体を使用するループスの処置

Publications (2)

Publication Number Publication Date
JP2023040241A JP2023040241A (ja) 2023-03-22
JP2023040241A5 true JP2023040241A5 (cg-RX-API-DMAC7.html) 2023-06-21

Family

ID=61827719

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019552040A Pending JP2020514386A (ja) 2017-03-22 2018-03-22 ヒト化抗cxcr5抗体を使用するループスの処置
JP2023003470A Pending JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗cxcr5抗体を使用するループスの処置
JP2025031035A Pending JP2025087764A (ja) 2017-03-22 2025-02-28 ヒト化抗cxcr5抗体を使用するループスの処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019552040A Pending JP2020514386A (ja) 2017-03-22 2018-03-22 ヒト化抗cxcr5抗体を使用するループスの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025031035A Pending JP2025087764A (ja) 2017-03-22 2025-02-28 ヒト化抗cxcr5抗体を使用するループスの処置

Country Status (7)

Country Link
US (1) US20240207397A1 (cg-RX-API-DMAC7.html)
EP (1) EP3601344A1 (cg-RX-API-DMAC7.html)
JP (3) JP2020514386A (cg-RX-API-DMAC7.html)
KR (2) KR20250052493A (cg-RX-API-DMAC7.html)
CN (1) CN110662767A (cg-RX-API-DMAC7.html)
AU (1) AU2018238540B2 (cg-RX-API-DMAC7.html)
IL (2) IL318907A (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof
KR20230004472A (ko) * 2020-04-21 2023-01-06 리제너론 파마슈티칼스 인코포레이티드 인간화 cxcl13 유전자를 갖는 비인간 동물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195023B1 (en) * 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
MX2017002381A (es) * 2014-08-22 2017-09-15 Sorrento Therapeutics Inc Proteinas de union de antigeno que se unen a cxcr5.

Similar Documents

Publication Publication Date Title
JP7223822B2 (ja) 抗ヒトパピローマウイルス16 e6 t細胞受容体
ES2328597T3 (es) Modulacion de nkg2d.
WO2021174595A1 (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
KR102866306B1 (ko) 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도
US20160333422A1 (en) Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
JP2019527194A5 (cg-RX-API-DMAC7.html)
JP7533897B2 (ja) 融合タンパク質およびその使用
JP2025087764A5 (cg-RX-API-DMAC7.html)
WO2022083675A1 (zh) 针对多种冠状病毒的单克隆抗体及应用
JP2021181450A (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
CN108350050A (zh) 淀粉样蛋白β中的表位及其构象选择性抗体
JP2022543658A5 (cg-RX-API-DMAC7.html)
CN112125975A (zh) Pd-l1和cd47双特异性融合蛋白及其医药用途
WO2022228183A1 (zh) 抗siglec15抗体及其制备方法和用途
TW202448962A (zh) 抗體、抗原結合片段和使用方法
BR112016030568B1 (pt) Método ex vivo para determinar se uma dose compreendendo uma proteína semelhante a anticorpo de região v dupla ou seu fragmento administrada a um indivíduo humano se liga especificamente a il-4 ou il-13 no indivíduo humano
IL277899B1 (en) Methods and compositions for treating yellow fever
US20230212272A1 (en) Isolated antigen binding protein and use thereof
CN120647760A (zh) 卷曲受体抗体及其用途
WO2024140820A1 (zh) 抗nkg2a抗体及其用途
WO2023179392A1 (zh) B7h3抗体及包含其的双功能抗体
TW202417478A (zh) 用於治療支氣管擴張的抗PcrV和Psl雙特異性藥物
JP6882440B2 (ja) 抗il4−il13二重特異性抗体
CN116710484A (zh) Wars中和抗体及其用途
JP2010540660A5 (cg-RX-API-DMAC7.html)